

Magda Siskova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1933869/publications.pdf>

Version: 2024-02-01

28
papers

463
citations

933447

10
h-index

713466

21
g-index

32
all docs

32
docs citations

32
times ranked

635
citing authors

#	ARTICLE	IF	CITATIONS
1	Cryptic aberrations may allow more accurate prognostic classification of patients with myelodysplastic syndromes and clonal evolution. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 396-405.	2.8	1
2	Lenalidomide treatment in lower risk myelodysplastic syndromes – The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in) <i>Tj ETQq0 0 0 rgBT / Overlock 40 Tf 50 69</i>	0.8	0
3	Molecular cytogenetic analysis of dicentric chromosomes in acute myeloid leukemia. <i>Leukemia Research</i> , 2016, 43, 51-57.	0.8	8
4	Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes. <i>Leukemia Research</i> , 2016, 42, 7-12.	0.8	27
5	High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide. <i>European Journal of Haematology</i> , 2015, 95, 27-34.	2.2	26
6	Involvement of deleted chromosome 5 in complex chromosomal aberrations in newly diagnosed myelodysplastic syndromes (MDS) is correlated with extremely adverse prognosis. <i>Leukemia Research</i> , 2014, 38, 537-544.	0.8	24
7	Clonal Heterogeneity in Patients with Myelodysplastic Syndromes (MDS) and Complex Karyotypes. <i>Blood</i> , 2014, 124, 859-859.	1.4	0
8	Transcription factors Fli1 and EKLF in the differentiation of megakaryocytic and erythroid progenitor in 5q- syndrome and in Diamond-Blackfan anemia. <i>Annals of Hematology</i> , 2013, 92, 11-18.	1.8	16
9	P-202 MDS development risk in CLL patients with prolonged cytopenia after fludarabine, cyclophosphamide and rituximab (FCR) regime. <i>Leukemia Research</i> , 2013, 37, S114-S115.	0.8	0
10	P-231 The role of Fli1 and p53 for the effective megakaryopoiesis in 5q-syndrome. <i>Leukemia Research</i> , 2013, 37, S127.	0.8	0
11	High Cereblon Expression In Lower Risk Myelodysplastic Syndromes With 5q Deletion Is Associated With The Efficacy Of Lenalidomide. <i>Blood</i> , 2013, 122, 1529-1529.	1.4	0
12	Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q- MDS (IPSS) <i>Tj ETQq0 0 0 rgBT / Overlock 10</i>	0.8	0
13	Recurrent chromosomal breakpoints in patients with myelodysplastic syndromes and complex karyotype versus fragile sites. <i>Leukemia Research</i> , 2012, 36, e125-e127.	0.8	1
14	Fludarabine, Cyclophosphamide and Rituximab (FCR) Related Prolonged Cytopenia Is Frequent and Adverse Factor Affecting Survival of Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2012, 120, 1790-1790.	1.4	0
15	Efficacy And Safety Of Administration Of Oral Iron Chelator Deferiprone In Patients With Early Myelodysplastic Syndrome. <i>Hemoglobin</i> , 2011, 35, 217-227.	0.8	31
16	Combination of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: Slovakian experience.. <i>Journal of Clinical Oncology</i> , 2011, 29, e14152-e14152.	1.6	1
17	P081 The questions on megakaryopoiesis in MDS patients with del(5q). <i>Leukemia Research</i> , 2009, 33, S105.	0.8	0
18	Oxidative DNA damage in bone marrow cells of patients with low-risk myelodysplastic syndrome. <i>Leukemia Research</i> , 2009, 33, 340-343.	0.8	41

#	ARTICLE	IF	CITATIONS
19	Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery. <i>Leukemia Research</i> , 2009, 33, 1567-1569.	0.8	5
20	Fli-1 and EKLf Gene Expression in Patients with MDS 5q- Syndrome.. <i>Blood</i> , 2009, 114, 2788-2788.	1.4	1
21	Frequency and Prognostic Impact of Complex Chromosomal Aberrations in Patients with Primary Myelodysplastic Syndromes and Del(5q).. <i>Blood</i> , 2009, 114, 1623-1623.	1.4	0
22	DNA instability in low-risk myelodysplastic syndromes: refractory anemia with or without ring sideroblasts. <i>Human Molecular Genetics</i> , 2008, 17, 2144-2149.	2.9	10
23	Molecular Cytogenetic Studies of Complex Karyotypes in Myelodysplastic Syndromes (MDS): Conventional Cytogenetics, FISH and Multiplex FISH (mFISH/mBAND). <i>Blood</i> , 2008, 112, 5075-5075.	1.4	0
24	Analysis of complex chromosomal rearrangements in adult patients with MDS and AML by multicolor FISH. <i>Leukemia Research</i> , 2007, 31, 39-47.	0.8	20
25	Structural aberrations of chromosome 7 revealed by a combination of molecular cytogenetic techniques in myeloid malignancies. <i>Cancer Genetics and Cytogenetics</i> , 2007, 173, 10-16.	1.0	17
26	Prognostic significance of del(20q) in patients with hematological malignancies. <i>Cancer Genetics and Cytogenetics</i> , 2005, 160, 188-192.	1.0	30
27	Accumulation of homoplasmic mtDNA point mutations in erythroblasts isolated from the bone marrow of patients with refractory anemia with ring sideroblasts (RARS). <i>Mitochondrion</i> , 2004, 4, 321-329.	3.4	2
28	Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. <i>British Journal of Haematology</i> , 1998, 100, 304-309.	2.5	192